Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test

Abbott Laboratories (NYSE:ABT) received CE Mark for its Cologuard Plus colorectal cancer test under the EU In Vitro Diagnostic Regulation. The approval clears Abbott to offer the noninvasive stool based screening test in select European markets for colorectal cancer detection. The Cologuard Plus authorization expands Abbott's diagnostics toolkit in Europe and broadens its potential customer base in cancer screening. The Cologuard Plus CE Mark is important, yet Abbott's broader healthcare...